| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.38 | $101.42 (0%) | 🛒 Add to cart |
| 60 | $2.71 | $202.84 $162.67 (20%) | 🛒 Add to cart |
| 90 | $2.50 | $304.26 $224.93 (26%) | 🛒 Add to cart |
| 120 | $2.38 | $405.67 $285.18 (30%) | 🛒 Add to cart |
| 180 | $2.26 | $608.51 $407.68 (33%) | 🛒 Add to cart |
| 270 | $2.19
Best per pill | $912.77 $592.44 (35%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.20 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $73.80 $70.29 (5%) | 🛒 Add to cart |
| 120 | $0.76 | $98.41 $91.38 (7%) | 🛒 Add to cart |
| 180 | $0.74 | $147.61 $132.55 (10%) | 🛒 Add to cart |
| 270 | $0.73 | $221.41 $195.81 (12%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $295.22 $258.06 (13%) | 🛒 Add to cart |
Similar products
More info:
diltiazem
Diltiazem hydrochloride represents one of the most versatile cardiovascular agents in our modern pharmacopeia, a calcium channel blocker with a fascinatingly specific electrophysiological profile that makes it particularly useful for rate control in atrial fibrillation while also providing robust antianginal effects. When I first started using diltiazem in the late 1990s, we primarily thought of it as just another calcium channel blocker, but over two decades of clinical application have revealed its unique niche in cardiovascular therapeutics that sets it apart from both dihydropyridines like amlodipine and non-dihydrophyridines like verapamil.
Atorlip 10: Effective Cholesterol Management for Cardiovascular Risk Reduction - Evidence-Based Review
Before we get to the formal monograph, let me give you the real story behind Atorlip 10. I remember when our cardiology department first started seeing the generic atorvastatin formulations hit the market - we had this naive optimism that cheaper statins would solve our adherence problems. Then the Atorlip 10 samples arrived from the manufacturer, and Dr. Chen from our lipid clinic just shook his head saying “another me-too product” during our Wednesday case conference.
buspar
Buspirone hydrochloride represents one of the more interesting anxiolytics in our modern pharmacopeia - it’s not a benzodiazepine, doesn’t cause significant sedation or dependence, yet effectively manages generalized anxiety. When I first encountered Buspar during my residency in the late 80s, we were all skeptical about this “non-sedating anxiety medication.” The initial clinical trials showed promise, but the real test came in daily practice. The drug’s unique mechanism targeting serotonin 5-HT1A receptors specifically intrigued me from the beginning.
calan
Calan, known generically as verapamil, represents one of the foundational calcium channel blockers in cardiovascular therapeutics. Initially developed for angina, its utility has expanded significantly across multiple cardiac and non-cardiac indications. What’s fascinating isn’t just its mechanism—blocking L-type calcium channels—but how this simple action creates such diverse clinical effects. We’ve moved far beyond the original 1980s understanding of Calan as just an anti-anginal agent. Calan: Comprehensive Cardiovascular and Migraine Management - Evidence-Based Review 1.
cardizem
Let me walk you through what we’ve learned about Cardizem over the years - not just from textbooks, but from the trenches of clinical practice. When I first started cardiology fellowship, I thought I understood calcium channel blockers. The textbooks made it seem straightforward. But real patients? They taught me the nuances you can’t find in any pharmaceutical package insert. Cardizem, known generically as diltiazem, belongs to the benzothiazepine class of calcium channel blockers.
coreg
Carvedilol, marketed under the brand name Coreg, represents a significant advancement in cardiovascular pharmacotherapy as a non-selective beta-blocker with additional alpha-1 adrenergic blocking properties. This unique dual mechanism distinguishes it from conventional beta-blockers and expands its therapeutic applications across multiple cardiovascular conditions. Initially developed in the 1980s and approved by the FDA in 1997, carvedilol has established itself as a cornerstone in managing heart failure, hypertension, and post-myocardial infarction care. The drug’s ability to simultaneously block β1, β2, and α1 receptors creates a comprehensive sympatholytic effect that addresses both the hemodynamic and neurohormonal aspects of cardiovascular disease progression.
Erythromycin: Effective Bacterial Infection Treatment - Evidence-Based Review
Erythromycin represents one of the foundational macrolide antibiotics discovered back in 1952 from Streptomyces erythreus. It’s fascinating how this compound bridged the gap between penicillin and newer antibiotics, especially for penicillin-allergic patients. We’ve used it across every conceivable bacterial infection over the decades—respiratory tract, skin, sexually transmitted diseases, you name it. The molecular structure features a 14-membered lactone ring with two sugar moieties, desosamine and cladinose, which is crucial for its antibacterial activity.
inderal
Propranolol hydrochloride, marketed under the brand name Inderal, represents one of the foundational beta-blockers in cardiovascular and neurological medicine. As a non-selective beta-adrenergic antagonist, it competitively blocks catecholamine effects at both β1 and β2 adrenergic receptors. This mechanism underlies its diverse clinical applications spanning from hypertension management to essential tremor control. The drug’s development in the 1960s by Sir James Black revolutionized angina treatment and earned him a Nobel Prize, though its utility has expanded far beyond original indications.
Innopran XL: Sustained Blood Pressure Control for Hypertension - Evidence-Based Review
Propranolol hydrochloride extended-release capsules – we’re talking about one of those foundational cardiovascular agents that somehow manages to remain both utterly conventional and surprisingly nuanced in clinical application. As a non-selective beta-adrenergic blocking agent, its core mechanism revolves around competitive antagonism at both β1 and β2 adrenergic receptors. What makes the XL formulation particularly interesting isn’t just the active pharmaceutical ingredient itself, but the delivery system – that extended-release mechanism that provides relatively consistent plasma concentrations over 24 hours with once-daily dosing.